Cytopia Vows Fight To Keep Avexa From Progen In All-Australia Battle
This article was originally published in PharmAsia News
Australia's Cytopia is urging shareholders of Avexa to vote for its firm to merge with the biotech in late March to stave off any new hostile takeovers. Cytopia CEO Andrew Macdonald said he is not through yet in his battle to keep Progen Pharmaceuticals from trying to obtain control of Avexa, and urged shareholders to ignore Progen's promise it is ready to begin commercializing Avexa's PI-88 drug and already is in talks with Taiwain regulators. Cytopia said in an interview the Progen assertion was just a smokescreen. (Click here for more
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.